NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus

Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK with a similar efficacy to BAFF inhibition in two...

Descrizione completa

Dettagli Bibliografici
Autori principali: Hans D. Brightbill, Eric Suto, Nicole Blaquiere, Nandhini Ramamoorthi, Swathi Sujatha-Bhaskar, Emily B. Gogol, Georgette M. Castanedo, Benjamin T. Jackson, Youngsu C. Kwon, Susan Haller, Justin Lesch, Karin Bents, Christine Everett, Pawan Bir Kohli, Sandra Linge, Laura Christian, Kathy Barrett, Allan Jaochico, Leonid M. Berezhkovskiy, Peter W. Fan, Zora Modrusan, Kelli Veliz, Michael J. Townsend, Jason DeVoss, Adam R. Johnson, Robert Godemann, Wyne P. Lee, Cary D. Austin, Brent S. McKenzie, Jason A. Hackney, James J. Crawford, Steven T. Staben, Moulay H. Alaoui Ismaili, Lawren C. Wu, Nico Ghilardi
Natura: Articolo
Lingua:English
Pubblicazione: Nature Portfolio 2018-01-01
Serie:Nature Communications
Accesso online:https://doi.org/10.1038/s41467-017-02672-0